DEC O 8 2004 LES

40/F

TO THE COMMISSIONER FOR PATENTS

ANTI-INFLAMMATORY, ANTINEOPLASTIC AND ANTIVIRAL ACTIVE MOLECULES

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

		CLAIM	S AS AMENI	JED	
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
otal Claims	46	- 52 =		X	
ndependent Slaims	25	- 26 =		x	
lultiple Depend	lent Claims (che	eck if applicabl	e)		
Extension for response within first month Other fee (please specify): Two Terminal Disclaimers IDS fee					560.00
OTAL ADDIT	ONAL FEE FO	OR THIS AME	NDMENT:		560.00
Large Entity				Small En	itity
	d foo io roquiro	d for this amoun	ndmont.		
	Il fee is require	u ioi tilis airiei	iament.		
Please charg	ge Deposit Acc	ount No.	ir	the amount of	\$
	copy of this she		•		
A check in th	ne amount of \$	560.00	to cover	the filing fee is	enclosed
=		DTO 2020			3.10.0004.
Tavinent Dv	Ciedii Caru. Fu	orm PTO-2038	is attached.		
			•		
		orized to char	ge and credit	Deposit Accour	nt No. <u>04-0100</u>
The Director				•	nt No. <u>04-0100</u>
The Director as described	is hereby auth I below. A dup	licate copy of t		•	nt No. <u>04-0100</u>
The Director as described x Credit ar	is hereby auth I below. A dup ny overpaymen	licate copy of to	this sheet is e	enclosed.	
The Director as described x Credit ar	is hereby auth I below. A dup ny overpaymen	licate copy of to	this sheet is e	enclosed.	nt No04-0100
The Director as described x Credit ar x Charge a	is hereby auth I below. A dup ny overpaymen any additional fili	licate copy of to	this sheet is e	enclosed.	
The Director as described x Credit ar x Charge a	is hereby auth I below. A dup ny overpaymen any additional fili	licate copy of to	this sheet is e	enclosed. ees required und	ler 37 CFR 1.16 and 1.17.
The Director as described x Credit ar x Charge a	is hereby auth I below. A dup ny overpaymen any additional fili flus	licate copy of to	this sheet is e	enclosed. ees required und	ler 37 CFR 1.16 and 1.17
The Director as described x Credit ar x Charge a licholas Sisti	is hereby auth I below. A dup ny overpaymen any additional fili flus	licate copy of to	this sheet is e	enclosed. ees required und	ler 37 CFR 1.16 and 1.17.
The Director as described as described as Credit are Charge as Cha	is hereby authorized below. A dupony overpayment any additional filiples. Io.: 54,453 BY P.C. York 10150-5	licate copy of the state of the	this sheet is e	enclosed. ees required und	ler 37 CFR 1.16 and 1.17

Express Mail Label No.	Dated:	

Docket No.: 03818/100L652-US1

Docket No.: 03818/100L652-US1

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Mladen Mercep et al.

Application No.: 10/616,046

Filed: July 8, 2003 Art Unit: 1623

For: NOVEL COMPOUNDS, COMPOSITIONS AS

CARRIERS FOR STEROID/NONSTEROID ANTI-INFLAMMATORY, ANTINEOPLASTIC AND ANTIVIRAL ACTIVE MOLECULES Examiner: E. Peselev

Confirmation No.: 9782

AMENDMENT IN RESPONSE TO NON-FINAL OFFICE ACTION

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

A petition for a one (1) month extension of time and the required fee is enclosed along with the required fee for filing a supplemental Information Disclosure Statement.

In response to the Office Action dated August 10, 2004 (Paper No. 08062004), please amend the above-identified U.S. patent application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 45 of this paper.

{W:\03818\100L652US1\00316689.DOC @@@@@@@@@@@@@@@}}